

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **ANGELALIGN TECHNOLOGY INC.**

**時代天使科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6699)**

### **(1) RE-DESIGNATION OF A DIRECTOR AND (2) RESIGNATION OF A DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Angelalign Technology Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that:

- (1) Mr. FENG Dai (“**Mr. Feng**”), a non-executive Director (“**Non-executive Director**”), has been re-designated and appointed as an executive Director (“**Executive Director**”) with effect from April 23, 2026 and will continue to serve as the chairman of the Board and the chairman of the nomination committee of the Board (“**Nomination Committee**”); and
- (2) Mr. SONG Xin (“**Mr. Song**”) has resigned as a Director with effect from April 23, 2026, and will continue to serve as the chief strategy officer of the Company (“**Chief Strategy Office**”).

The Board will continue to make efforts to enhance its international representation and perspectives, in line with the Group’s expanding global footprint and open, collaborative culture.

### **RE-DESIGNATION OF A DIRECTOR**

The Board hereby announces that Mr. Feng, a Non-executive Director, has been re-designated and appointed as an Executive Director with effect from April 23, 2026.

Mr. Feng has served as a Director of the Company for 14 years, most recently as the Non-executive Director and chairman of the Board and the chairman of the Nomination Committee. He has deep experience in medical device innovation and business development around the world. He has made significant contributions to the Company in strategy, corporate governance, risk management, and business development. The Board believes his appointment as an Executive Director, and serving as the executive chairman of the Board, will further strengthen the Group’s capabilities in above critical areas and drive its sustainable growth.

The biographical details of Mr. Feng are as follows:

Mr. FENG Dai (馮岱), aged 50, is our chairman of the Board and re-designated and appointed as an Executive Director with effect from April 23, 2026. Mr. Feng is primarily responsible for strategy, corporate governance, risk management and business development of our Group. Mr. Feng joined our Group in May 2012.

Since 2015, Mr. Feng has been a co-founder of CareCapital Advisors, an investor and strategy advisor in oral health innovations, overseeing a portfolio of technology companies, and advising entrepreneurs as well as academic and industry leaders. He also serves as a member of the Board of Fellows of the Harvard School of Dental Medicine, as the Co-Chairman of the International Orthodontic Foundation, and from 2018 to 2023 as a director of the Board of The Forsyth Institute, a leading oral health research organization in Boston. He was employed from 2004 to 2014 at Warburg Pincus, a private equity partnership, and served as its partner for healthcare venture and growth investing in Asia. He was previously employed at Goldman Sachs, an investment bank, in various years between 1997 and 2004.

Mr. Feng graduated from Harvard University with a bachelor's degree in engineering sciences in 1997.

Mr. Feng is deemed to be interested in 87,168,400 shares of the Company (the “**Shares**”) within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), by virtue of his control over CareCapital OrthoTech Limited, which holds such Shares. Such interest represents a deemed interest arising from the voting rights attached to the relevant Shares.

Mr. Feng has entered into a service contract with the Company for an initial term of three years commencing from April 23, 2026. Mr. Feng will be subject to retirement by rotation and re-election in accordance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the articles of association of the Company. Mr. Feng will receive remuneration as an Executive Director to be determined by the Board with reference to the recommendation of the remuneration committee of the Board based on his duties and responsibilities with the Company, his experience and the prevailing market conditions. Mr. Feng will retain as the chairman of the Nomination Committee, and will abstain from voting for determining on his remuneration by either of the remuneration committee of the Board or the Board, as applicable, in accordance with the Listing Rules and relevant terms of references.

Save as disclosed in this announcement and in the Company's annual report for the year ended December 31, 2024, other than serving as an independent director for WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (stock codes: 2359.HK; 603259.SH) from December 2018 to January 2025 and Sling Group Holdings Limited (stock code: 8285.HK) from December 2017 to August 2024, respectively, Mr. Feng has confirmed that he (i) has not held any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this re-designation; (ii) does not have any interest in any Shares, underlying Shares or debentures of the Company within the meaning of Part XV of the SFO; (iii) does not hold any other positions in the Company or its subsidiaries; and (iv) does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed in this announcement, there are no other matters which need to be brought to the attention of the shareholders of the Company the (“**Shareholders**”) regarding the re-designation of Mr. Feng or any other information relating to Mr. Feng that needs to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Mr. Feng on his new position in the Company.

## **RESIGNATION OF A DIRECTOR**

The Board announces that with effect from April 23, 2026, Mr. Song has resigned as a Director due to work arrangements. Mr. Song will continue to serve as the Chief Strategy Officer.

Mr. Song has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation as a Director that needs to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its sincere gratitude to Mr. Song for his contributions to the Company during his tenure of office as a Director, and look forward to Mr. Song's continued leadership in his role as Chief Strategy Officer.

**The Board will continue to make efforts to enhance its international representation and perspectives, in line with the Group's expanding global footprint and open, collaborative culture.**

By Order of the Board  
**Angelalign Technology Inc.**  
**Mr. FENG Dai**  
*Chairman*

Hong Kong, April 23, 2026

*As at the date of this announcement, the Board comprises Mr. FENG Dai, Mr. HU Jiezhong, Mr. HUANG Kun and Ms. DONG Li as executive Directors; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.*